OREANDA-NEWS. September 01, 2015. The shareholders have appointed Dr Andreas Neumann as a new member of the Board of Managing Directors. He will join the Boehringer Ingelheim Board of Managing Directors on 1. October 2015 and assume responsibility for the Corporate Board Division Human Resources. The fully qualified lawyer joined the company in 2011 and has managed the Corporate Division Legal. Since early 2015 he is also in charge of the Corporate Division Human Resources.

Christian Boehringer, Chairman of the Shareholder Committee, stated: "Through the autonomous staffing of the Corporate Board Division Human Resources, we wish to highlight the importance of this area and orientate our long-term, international personnel development and personnel planning to future demands." Professor Andreas Barner, Chairman of the Boehringer Ingelheim Board of Managing Directors, said: "We are convinced that Andreas Neumann, in light of the significant changes occurring within the framework conditions, as well as various demographic and technological transformations, will reinforce our focus on the labour market that is going through global changes."

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.